Biogen Announces Departure of Tony Kingsley
October 09 2015 - 7:30AM
Business Wire
John Cox to Lead Commercial Operations on
Interim Basis
Biogen (NASDAQ: BIIB) today announced that Tony Kingsley,
executive vice president, Global Commercial Operations, will leave
the company and a search has been initiated for a permanent
replacement. In the interim his responsibilities will be assumed by
John G. Cox, executive vice president, Pharmaceutical Operations
& Technology.
“Tony has made significant contributions to Biogen,” said George
A. Scangos, Ph.D., chief executive officer. “He led the successful
introduction of five important new products and helped serve
patients around the world with our life-transforming therapies. All
of us wish Tony the best in his future endeavors.”
John Cox has served in his current position since June 2010. He
joined Biogen in 2003 and has held several senior executive
positions with us, including Senior Vice President of Technical
Operations, Senior Vice President of Global Manufacturing, and Vice
President of Manufacturing and General Manager of Biogen’s
operations in Research Triangle Park, North Carolina.
“We are pleased that John will lead our commercial operations on
an interim basis,” Scangos continued. “His 12 years at Biogen and
in-depth knowledge of our pharmaceutical and commercial operations
give us great confidence that we will continue to execute on the
commercial opportunities at-hand as we search for a permanent
leader.”
Kingsley joined Biogen in January 2010 as Senior Vice President,
U.S. Commercial Operations and has been in his current position
since November 2011. During his tenure, Biogen introduced five new
therapies, including successfully launching TECFIDERA® (dimethyl
fumarate), the most-prescribed oral treatment for multiple
sclerosis today. His leadership contributed to the company’s
revenue growth of 108% during his tenure. Prior to his time at
Biogen, Tony served as Senior Vice President and General Manager of
the Gynecological Surgical Products business at Hologic, Inc.,
Division President, Diagnostic Products at Cytyc Corp., and was a
Partner at McKinsey & Company.
About Biogen
Through cutting-edge science and medicine, Biogen discovers,
develops and delivers to patients worldwide innovative therapies
for the treatment of neurodegenerative diseases, hematologic
conditions and autoimmune disorders. Founded in 1978, Biogen is one
of the world’s oldest independent biotechnology companies and
patients worldwide benefit from its leading multiple sclerosis and
innovative hemophilia therapies. For product labeling, press
releases and additional information about the company, please visit
www.biogen.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151009005078/en/
BiogenMedia Contact:Jason Glashow, +1
781-464-3260public.affairs@biogen.comorInvestor Contact:Carlo
Tanzi, Ph.D., +1 781-464-2442IR@biogen.com
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Apr 2023 to Apr 2024